Video

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

Author(s):

Peter Voorhees, MD, Atrium Health

Related Videos
C. Ola Landgren, MD, PhD
Justin M. Watts, MD
David Samuel Dicapua Siegel, MD
Mazyar Shadman, MD, MPH
Management of Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoietin Stimulating Agent (ESA) Treatment
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alfred L. Garfall, MD, MS
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Related Content
Mark R. Litzow, MD
July 24th 2024

Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

FDA
July 23rd 2024

FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Image Credit: ©Dr_Microbe - stock.adobe.com
July 19th 2024

EMA Accepts MAA for Belantamab Mafodotin Combos in R/R Multiple Myeloma

C. Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center
July 19th 2024

Four-Drug Regimens Escalate the SOC for Newly Diagnosed Multiple Myeloma